Modulating WASp
to transform outcomes
in cancer and
autoimmune disease.
We are developing first-in-class small molecule modulators of WASp to address high unmet need with precision and purpose.
Our purpose
Modulating WASp in two directions
Wiskott-Aldrich Syndrome protein, or WASp, plays an important role in actin organisation and immune cell function. Its activity influences processes including cell migration, proliferation, signalling, cytotoxicity and phagocytosis.
BIMINI is developing small molecules that modulate WASp in opposite directions, creating therapeutic opportunities in both cancer and autoimmune disease.
WASp activation
Our activator programme is designed to increase WASp activity in cancer cells that are dependent on the pathway. Excessive activation drives actin dysregulation, genomic instability and apoptosis.
WASp inhibition
Our inhibitor programme is designed to reduce WASp function in overactive immune cells. By increasing WASp degradation, the approach aims to reduce pathological immune activity and restore immune balance.
Pipeline
A focused preclinical pipeline
BIMINI is advancing a portfolio of first-in-class WASp modulators across oncology and autoimmune disease. Our most advanced activator programme is progressing through lead optimisation for acute myeloid leukemia, supported by in vitro and in vivo proof-of-concept data In parallel, we are advancing WASp inhibition for rheumatoid arthritis, where the ZF-09 series has demonstrated in vivo proof of concept.
About us
Building a new therapeutic approach around WASp
BIMINI was founded in 2019 and is based in Leiden, the Netherlands.
Since inception, the company has built a portfolio of small molecule WASp modulators, generated preclinical evidence across oncology and autoimmune disease and secured approximately €6 million in dilutive and non-dilutive funding.
Our work combines medicinal chemistry, disease biology, computational modelling and preclinical development with a network of scientific, clinical and industry partners.
2019
Founded
Privately held
4+
Team members
Scientists and innovators
2
Therapeutic programs
Oncology and autoimmunity
1
Focused mission
Transform patient outcomes
Partnering
From differentiated biology to new medicines
Our goal is to translate the therapeutic potential of WASp modulation into medicines for patients with diseases where new mechanisms of action are needed.